- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 510547, 7 pages
TRAF1-C5 Affects Quality of Life in Patients with Primary Biliary Cirrhosis
1Liver Research Laboratories, Pomeranian Medical University, Aleja Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland
2Liver Unit, Department of General Surgery and Liver Transplantation, Warsaw Medical University, ul. Banacha 1a, 02-097 Warsaw, Poland
3Medical Biology Laboratory, Pomeranian Medical University, Aleja Powstańców Wielkopolskich 72 70-111 Szczecin, Poland
4Institute of Liver Studies, King’s College London School of Medicine, King’s College Hospital, Denmark Hill, London SE5 9RS, UK
Received 6 March 2013; Accepted 6 April 2013
Academic Editor: Eirini I. Rigopoulou
Copyright © 2013 Joanna Raszeja-Wyszomirska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- M. M. Kaplan and M. E. Gershwin, “Primary biliary cirrhosis,” The New England Journal of Medicine, vol. 353, no. 12, pp. 1261–1273, 2005.
- D. P. Bogdanos and L. Komorowski, “Disease-specific autoantibodies in primary biliary cirrhosis,” Clinica Chimica Acta, vol. 412, no. 7-8, pp. 502–512, 2011.
- D. P. Bogdanos, P. Invernizzi, I. R. Mackay, and D. Vergani, “Autoimmune liver serology: current diagnostic and clinical challenges,” World Journal of Gastroenterology, vol. 14, no. 21, pp. 3374–3387, 2008.
- D. P. Bogdanos, D. S. Smyk, E. I. Rigopoulou et al., “Twin studies in autoimmune disease: genetics, gender and environment,” Journal of Autoimmunity, vol. 38, no. 2-3, pp. J156–J169, 2012.
- C. Selmi and M. E. Gershwin, “The role of environmental factors in primary biliary cirrhosis,” Trends in Immunology, vol. 30, no. 8, pp. 415–420, 2009.
- M. E. Gershwin and I. R. Mackay, “The causes of primary biliary cirrhosis: convenient and inconvenient truths,” Hepatology, vol. 47, no. 2, pp. 737–745, 2008.
- G. M. Hirschfield, X. Liu, C. Xu et al., “Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants,” The New England Journal of Medicine, vol. 360, no. 24, pp. 2544–2555, 2009.
- G. M. Hirschfield, X. Liu, Y. Han et al., “Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis,” Nature Genetics, vol. 42, no. 8, pp. 655–657, 2010.
- X. Liu, P. Invernizzi, Y. Lu et al., “Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis,” Nature Genetics, vol. 42, no. 8, pp. 658–660, 2010.
- G. F. Mells, J. A. B. Floyd, K. I. Morley et al., “Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis,” Nature Genetics, vol. 43, no. 4, pp. 332–333, 2011.
- B. D. Juran, G. M. Hirschfield, P. Invernizzi et al., “Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk Variants,” Human Molecular Genetics, vol. 21, no. 23, Article ID dds359, pp. 5209–5221, 2012.
- J. Z. Liu, M. A. Almarri, D. J. Gaffney et al., “Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis,” Nature Genetics, vol. 44, no. 10, pp. 1137–1141, 2012.
- M. Nakamura, N. Nishida, M. Kawashima et al., “Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population,” The American Journal of Human Genetics, vol. 91, no. 4, pp. 721–728, 2012.
- A. Lleo, M. E. Gershwin, A. Mantovani, and P. Invernizzi, “Towards common denominators in primary biliary cirrhosis: the role of IL-12,” Journal of Hepatology, vol. 56, no. 3, pp. 731–733, 2012.
- A. Tanaka, S. Quaranta, A. Mattalia et al., “The tumor necrosis factor-α promoter correlates with progression of primary biliary cirrhosis,” Journal of Hepatology, vol. 30, no. 5, pp. 826–829, 1999.
- D. E. J. Jones, F. E. Watt, J. Grove et al., “Tumour necrosis factor-α promoter polymorphisms in primary biliary cirrhosis,” Journal of Hepatology, vol. 30, no. 2, pp. 232–236, 1999.
- P. Donaldson, S. Veeramani, A. Baragiotta et al., “Cytotoxic T-lymphocyte-associated antigen-4 single nucleotide polymorphisms and haplotypes in primary biliary cirrhosis,” Clinical Gastroenterology and Hepatology, vol. 5, no. 6, pp. 755–760, 2007.
- A. Kempinska-Podhorodecka, Z. Shums, E. Wunsch et al., “TRAF1 gene polymorphism correlates with the titre of Gp210 antibody in patients with primary biliary cirrhosis,” Clinical and Developmental Immunology, vol. 2012, Article ID 487521, 7 pages, 2012.
- F. A. S. Kurreeman, D. Rocha, J. Houwing-Duistermaat et al., “Replication of the tumor necrosis factor receptor-associated factor 1/complement component 5 region as a susceptibility locus for rheumatoid arthritis in a european family-based study,” Arthritis and Rheumatism, vol. 58, no. 9, pp. 2670–2674, 2008.
- M. I. Zervou, P. Sidiropoulos, E. Petraki et al., “Association of a TRAF1 and a STAT4 gene polymorphism with increased risk for rheumatoid arthritis in a genetically homogeneous population,” Human Immunology, vol. 69, no. 9, pp. 567–571, 2008.
- R. M. Plenge, M. Seielstad, L. Padyukov et al., “TRAF1-C5 as a risk locus for rheumatoid arthritis: a genomewide study,” The New England Journal of Medicine, vol. 357, no. 12, pp. 1199–1209, 2007.
- F. A. S. Kurreeman, G. N. Goulielmos, B. Z. Alizadeh et al., “The TRAF1-C5 region on chromosome 9q33 is associated with multiple autoimmune diseases,” Annals of the Rheumatic Diseases, vol. 69, no. 4, pp. 696–699, 2010.
- S. Y. Lee and Y. Choi, “TRAF1 and its biological functions,” Advances in Experimental Medicine and Biology, vol. 597, pp. 25–31, 2007.
- L. Bao and R. J. Quigg, “Complement in Lupus Nephritis: the good, the bad, and the unknown,” Seminars in Nephrology, vol. 27, no. 1, pp. 69–80, 2007.
- S. H. Sacks, “Complement fragments C3a and C5a: the salt and pepper of the immune response,” European Journal of Immunology, vol. 40, no. 3, pp. 668–670, 2010.
- J. P. Atkinson, “C5a and Fcγ receptors: a mutual admiration society,” Journal of Clinical Investigation, vol. 116, no. 2, pp. 304–306, 2006.
- R. E. Schmidt and J. E. Gessner, “Fc receptors and their interaction with complement in autoimmunity,” Immunology Letters, vol. 100, no. 1, pp. 56–67, 2005.
- V. Barak, C. Selmi, M. Schlesinger et al., “Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis,” Journal of Autoimmunity, vol. 33, no. 3-4, pp. 178–182, 2009.
- M. Schlesinger, C. Benbassat, and Y. Shoenfeld, “Complement profile in primary biliary cirrhosis,” Immunologic Research, vol. 11, no. 2, pp. 98–103, 1992.
- M. G. Swain, P. Beck, K. Rioux, and T. Le, “Augmented interleukin-1β-induced depression of locomotor activity in cholestatic rats,” Hepatology, vol. 28, no. 6, pp. 1561–1565, 1998.
- S. M. Kerfoot, C. D'Mello, H. Nguyen et al., “TNF-α-secreting monocytes are recruited into the brain of cholestatic mice,” Hepatology, vol. 43, no. 1, pp. 154–162, 2006.
- M. Maes, F. N. Twisk, and K. Ringel, “Inflammatory and cell-mediated immune biomarkers in myalgic encephalomyelitis/chronic fatigue syndrome and depression: inflammatory markers are higher in myalgic encephalomyelitis/chronic fatigue syndrome than in depression,” Psychotherapy and Psychosomatics, vol. 81, no. 5, pp. 286–295, 2012.
- G. E. Hermann and R. C. Rogers, “TNFα: a trigger of autonomic dysfunction,” Neuroscientist, vol. 14, no. 1, pp. 53–67, 2008.
- Y. Jiang, R. Deacon, D. C. Anthony, and S. J. Campbell, “Inhibition of peripheral TNF can block the malaise associated with CNS inflammatory diseases,” Neurobiology of Disease, vol. 32, no. 1, pp. 125–132, 2008.
- M. Fotin-Mleczek, F. Henkler, A. Hausser et al., “Tumor Necrosis Factor Receptor-associated Factor (TRAF) 1 Regulates CD40-induced TRAF2-mediated NF-κB Activation,” Journal of Biological Chemistry, vol. 279, no. 1, pp. 677–685, 2004.
- P. Xie, B. S. Hostager, M. E. Munroe, C. R. Moore, and G. A. Bishop, “Cooperation between TNF receptor-associated factors 1 and 2 in CD40 signaling,” Journal of Immunology, vol. 176, no. 9, pp. 5388–5400, 2006.
- European Association for the Study of the Liver, “EASL Clinical Practice Guidelines: management of cholestatic liver diseases,” Journal of Hepatology, vol. 51, no. 2, pp. 237–267, 2009.
- J. E. Ware Jr. and C. D. Sherbourne, “The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection,” Medical Care, vol. 30, no. 6, pp. 473–483, 1992.
- A. Jacoby, A. Rannard, D. Buck et al., “Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis,” Gut, vol. 54, no. 11, pp. 1622–1629, 2005.
- L. Montali, A. Tanaka, P. Riva et al., “A short version of a HRQoL questionnaire for Italian and Japanese patients with Primary Biliary Cirrhosis,” Digestive and Liver Disease, vol. 42, no. 10, pp. 718–723, 2010.
- J. Zhu, D. Zhang, F. Wu et al., “Single nucleotide polymorphisms at the TRAF1/C5 locus are associated with rheumatoid arthritis in a Han Chinese population,” BMC Medical Genetics, vol. 12, article 53, 2011.
- S. Redler, F. F. Brockschmidt, L. Forstbauer et al., “The TRAF1/C5 locus confers risk for familial and severe alopecia areata,” British Journal of Dermatology, vol. 162, no. 4, pp. 866–869, 2010.
- C. Potter, S. Eyre, A. Cope, J. Worthington, and A. Barton, “Investigation of association between the TRAF family genes and RA susceptibility,” Annals of the Rheumatic Diseases, vol. 66, no. 10, pp. 1322–1326, 2007.
- K. Nishimoto, Y. Kochi, K. Ikari et al., “Association study of TRAF1-C5 polymorphisms with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese,” Annals of the Rheumatic Diseases, vol. 69, no. 2, pp. 368–373, 2010.
- L. B. Hughes, R. J. Reynolds, E. E. Brown et al., “Most common single-nucleotide polymorphisms associated with rheumatoid arthritis in persons of European ancestry confer risk of rheumatoid arthritis in African Americans,” Arthritis Care and Research, vol. 62, no. 12, pp. 3547–3553, 2010.
- T. U. Han, S. Y. Bang, C. Kang, and S. C. Bae, “TRAF1 polymorphisms associated with rheumatoid arthritis susceptibility in asians and in caucasians,” Arthritis and Rheumatism, vol. 60, no. 9, pp. 2577–2584, 2009.
- R. Knevel, D. P. de Rooy, P. K. Gregersen, E. Lindqvist, et al., “Studying associations between variants in TRAF1-C5 and TNFAIP3-OLIG3 and the progression of joint destruction in rheumatoid arthritis in multiple cohorts,” Annals of the Rheumatic Diseases, vol. 71, no. 10, pp. 1753–1755, 2012.
- R. H. Mohamed, H. F. Pasha, and E. E. El-Shahawy, “Influence of TRAF1/C5 and STAT4 genes polymorphisms on susceptibility and severity of rheumatoid arthritis in Egyptian population,” Cellular Immunology, vol. 273, no. 1, pp. 67–72, 2012.
- A. W. Morgan, J. I. Robinson, P. G. Conaghan et al., “Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort,” Arthritis Research and Therapy, vol. 12, no. 2, article R57, 2010.
- J. Wesierska-Gadek, E. Penner, P. M. Battezzati et al., “Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis,” Hepatology, vol. 43, no. 5, pp. 1135–1144, 2006.
- M. Nakamura, H. Kondo, T. Mori et al., “Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis,” Hepatology, vol. 45, no. 1, pp. 118–127, 2007.
- S. Itoh, T. Ichida, T. Yoshida et al., “Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis,” Journal of Gastroenterology and Hepatology, vol. 13, no. 3, pp. 257–265, 1998.
- J. Visser, W. Graffelman, B. Blauw et al., “LPS-induced IL-10 production in whole blood cultures from chronic fatigue syndrome patients is increased but supersensitive to inhibition by dexamethasone,” Journal of Neuroimmunology, vol. 119, no. 2, pp. 343–349, 2001.
- A. T. White, A. R. Light, R. W. Hughen et al., “Severity of symptom flare after moderate exercise is linked to cytokine activity in chronic fatigue syndrome,” Psychophysiology, vol. 47, no. 4, pp. 615–624, 2010.
- I. Pavese, F. Satta, F. Todi et al., “High serum levels of TNF-α and IL-6 predict the clinical outcome of treatment with human recombinant erythropoietin in anaemic cancer patients,” Annals of Oncology, vol. 21, no. 7, pp. 1523–1528, 2009.
- R. E. Poupon, Y. Chrétien, O. Chazouillères, R. Poupon, and J. Chwalow, “Quality of life in patients with primary biliary cirrhosis,” Hepatology, vol. 40, no. 2, pp. 489–494, 2004.
- Z. M. Younossi, M. L. Kiwi, N. Boparai, L. L. Price, and G. Guyatt, “Cholestatic liver diseases and health-related quality of life,” The American Journal of Gastroenterology, vol. 95, no. 2, pp. 497–502, 2000.
- G. L. H. Wong, F. M. Y. Law, V. W. S. Wong et al., “Health-related quality of life in Chinese patients with primary biliary cirrhosis,” Journal of Gastroenterology and Hepatology, vol. 23, no. 4, pp. 592–598, 2008.
- E. D. Sogolow, J. N. Lasker, and L. M. Short, “Fatigue as a major predictor of quality of life in women with autoimmune liver disease. The case of primary biliary cirrhosis,” Women's Health Issues, vol. 18, no. 4, pp. 336–342, 2008.
- H. L. Tillmann, M. Wiese, Y. Braun et al., “Quality of life in patients with various liver diseases: patients with HCV show greater mental impairment, while patients with PBC have greater physical impairment,” Journal of Viral Hepatitis, vol. 18, no. 4, pp. 252–261, 2011.